The company has developed the mfloDx® technology platform, which can detect TB-causing bacteria and drug resistance profiles in less than 3 hours from patients' sputum samples. Empe Diagnostics' diagnostic kits provide confirmatory point-of-care diagnostics for TB and Sexually Transmitted Infections, helping patients receive early-stage treatment. The company's first product, miniMDR-TB, is available for research use, and they plan to expand their portfolio to include more sexually transmitted diseases.